Podcast

June 30, 2022

Managed Care Cast Presents: ILD Peer Exchange—Treatment Goals in ILD, Part 1

In part 1 of this 2-part podcast, a panel of experts discusses treatment goals in patients with interstitial lung disease (ILD) and reviews of treatment paradigms and standard of care therapies

Today we are bringing you part 1 of a 2-part sponsored podcast series discussing treatment goals in insterstitial lung disease (ILD). The discussion was moderated by Ryan Haumschild, PharmD, director of Pharmacy Services at Emory Healthcare and Winship Cancer Institute.

The topics of conversation for today’s podcast include treatment goals in patients with ILD and a review of treatment paradigms and standard of care therapies.

Listen above or through one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify

Related Videos

Eneline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA

Related Content

Roadtorecovery | Image Credit: © jayzynism-stock.adobe.com

December 6th 2024

5 Innovative Approaches to Advance Recovery Care

National Recovery Month is recognized each year in September, and for 2024, we marked the month with a special podcast and exclusive video series with our Strategic Alliance Partner, UPMC Health Plan.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

COPD Stakeholder Summit—Individualizing Treatment and Improving Outcomes, Part 2

March 25th 2021

COPD Stakeholder Summit—Individualizing Treatment and Improving Outcomes, Part 2

In part 2 of the COPD Stakeholder Summit, a panel of experts discuss personalized approaches to COPD management and treatment efficacy.

Managed Care Cast Thumbnail

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

Related Content

Roadtorecovery | Image Credit: © jayzynism-stock.adobe.com

December 6th 2024

5 Innovative Approaches to Advance Recovery Care

National Recovery Month is recognized each year in September, and for 2024, we marked the month with a special podcast and exclusive video series with our Strategic Alliance Partner, UPMC Health Plan.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

COPD Stakeholder Summit—Individualizing Treatment and Improving Outcomes, Part 2

March 25th 2021

COPD Stakeholder Summit—Individualizing Treatment and Improving Outcomes, Part 2

In part 2 of the COPD Stakeholder Summit, a panel of experts discuss personalized approaches to COPD management and treatment efficacy.

Managed Care Cast Thumbnail

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions